Recent Advances in Nasopharyngeal Cancer Management: From Diagnosis
to Theranostics

Rajaa      Benzeid; Amina      Gihbid; Nadia      Benchekroun; Nezha      Tawfiq; Abdellatif      Benider; Mohammed      Attaleb; Abdelkarim      Filali Maltouf; Mohammed      El Mzibri; Meriem      Khyatti; Imane      Chaoui
Abstract

Nasopharyngeal cancer (NPC) is one of the most common head and neck cancers. NPC differs significantly from other cancers in its etiology, epidemiology, clinical behavior, and treatment. Being highly radiosensitive, the standard treatment for NPC is radiotherapy. However, radioresistance hampers the success of treatment and may cause local recurrence and distant metastases in NPC patients. In this review, we discuss the updated protocols for NPC diagnosis and treatment based on recent literature with an emphasis on the mechanisms of radioresistance at the molecular level with a special focus on genetic and epigenetic events, affecting genes involved in xenobiotic detoxification and DNA repair. We also highlight the importance of some cellular and Epstein Barr viral miRNAs targeting specific DNA repair factors and consequently promoting NPC radioresistance. These molecular markers may serve as promising tools for diagnosis, prognosis, and radioresistance prediction to guide theranostics of patients with NPC in the future.
[1]
Pan XX, Liu YJ, Yang W, Chen YF, Tang WB, Li CR. Histological subtype remains a prognostic factor for survival in nasopharyngeal carcinoma patients. Laryngoscope  2020; 130(3): E83-8.
 [http://dx.doi.org/10.1002/lary.28099] [PMID:  31188486]

[2]
Lim SW, Kamalden TMIT. Radiation-induced sarcoma post radiotherapy treatment of nasopharyngeal carcinoma. Int J Health Sci Res  2021; 11: 111-3.

[3]
Aksoy A, Elkiran E, Harputluoglu H, Dagli A, Isikdogan A, Urakci Z. Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma? J Cancer Res Ther  2019; 15(3): 550-5.
 [http://dx.doi.org/10.4103/0973-1482.206865] [PMID:  31169219]

[4]
Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet  2019; 394(10192): 64-80.
 [http://dx.doi.org/10.1016/S0140-6736(19)30956-0] [PMID:  31178151]

[5]
Rickinson AB, Lo KW. Nasopharyngeal Carcinoma: A HistoryNasopharyngeal Carcinoma: From ethiology to practice.  Academic Press 2019; pp. 1-16.
 [http://dx.doi.org/10.1016/B978-0-12-814936-2.00001-8]

[6]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2018; 68(6): 394-424.
 [http://dx.doi.org/10.3322/caac.21492] [PMID:  30207593]

[7]
Wang HY, Chang YL, To KF, et al. A new prognostic histopathologic classification of nasopharyngeal carcinoma. Chin J Cancer  2016; 35(1): 41.
 [http://dx.doi.org/10.1186/s40880-016-0103-5] [PMID:  27146632]

[8]
Tabuchi K, Nakayama M, Nishimura B, Hayashi K, Hara A. Early detection of nasopharyngeal carcinoma. Int J Otolaryngol  2011; 2011: 1-6.
 [http://dx.doi.org/10.1155/2011/638058] [PMID:  21716698]

[9]
Verhoeven R, Tong S, Zong J, et al. NF-κB Signaling Regulates Epstein-Barr Virus BamHI-Q-Driven EBNA1 Expression. Cancers   2018; 10(4): 119.
 [http://dx.doi.org/10.3390/cancers10040119] [PMID:  29659505]

[10]
Verhoeven RJA, Tong S, Zhang G, et al. NF-κB signaling regulates expression of epstein-barr virus bart micrornas and long noncoding rnas in nasopharyngeal carcinoma. J Virol  2016; 90(14): 6475-88.
 [http://dx.doi.org/10.1128/JVI.00613-16] [PMID:  27147748]

[11]
Huang SH, Chen ZJ, O’Sullivan B. Nasopharyngeal carcinoma— clinical aspects. In: Nasopharyngeal Carcinoma.  Academic Press 2019; pp. 359-68. b
 [http://dx.doi.org/10.1016/B978-0-12-814936-2.00017-1]

[12]
Chen ZT, Liang ZG, Zhu XD. A review: proteomics in nasopharyngeal carcinoma. Int J Mol Sci  2015; 16(12): 15497-530.
 [http://dx.doi.org/10.3390/ijms160715497] [PMID:  26184160]

[13]
Zanoni DK, Patel SG, Shah JP. Changes in the 8th Edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: Rationale and implications.  Curr Oncol Rep.   2019; 21: p. (6)52.

[14]
Ouyang PY, Xiao Y, You KY, et al. Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi. Oral Oncol 2017; 72: 65-72.

[15]
Duan W, Xiong B, Tian T, Zou X, He Z, Zhang L. Radiomics in nasopharyngeal carcinoma. Clin Med Insights Oncol  2022; 16: 11795549221079186.
 [http://dx.doi.org/10.1177/11795549221079186] [PMID:  35237090]

[16]
Tang LQ, Li CF, Li J, et al. Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma. J Natl Cancer Inst  2016; 108(1): djv291.
 [http://dx.doi.org/10.1093/jnci/djv291] [PMID:  26467665]

[17]
Liu GY, Lv X, Wu YS, et al. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. Cancer Commun  2018; 38(1): 21.
 [http://dx.doi.org/10.1186/s40880-018-0283-2] [PMID:  29764487]

[18]
Xu C, Zhang LH, Chen YP, et al. Chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma: a systemic review and meta-analysis of 2138 patients. J Cancer  2017; 8(2): 287-97.
 [http://dx.doi.org/10.7150/jca.17317] [PMID:  28243333]

[19]
Huang L, Hu C, Chao H, et al. Drug-resistant endothelial cells facilitate progression, EMT and chemoresistance in nasopharyngeal carcinoma via exosomes. Cell Signal  2019; 63: 109385.
 [http://dx.doi.org/10.1016/j.cellsig.2019.109385] [PMID:  31394194]

[20]
Al Tamimi A, Zaheer S, Ng D, Osmany S. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography imaging of metastatic nasopharyngeal cancer with emphasis on the distribution of bone metastases. World J Nucl Med  2017; 16(3): 192-6.
 [http://dx.doi.org/10.4103/1450-1147.207273] [PMID:  28670176]

[21]
Feng Q, Liang J, Wang L, Ge X, Ding Z, Wu H. A diagnosis model in nasopharyngeal carcinoma based on PET/MRI radiomics and semiquantitative parameters. BMC Med Imaging  2022; 22(1): 150.
 [http://dx.doi.org/10.1186/s12880-022-00883-6] [PMID:  36038819]

[22]
Xie C, Vardhanabhuti V. PET/CT: Nasopharyngeal cancers. PET Clin  2022; 17(2): 285-96.

[23]
Goh J, Lim K. Imaging of nasopharyngeal carcinoma. Ann Acad Med Singap  2009; 38(9): 809-16.
 [http://dx.doi.org/10.47102/annals-acadmedsg.V38N9p809] [PMID:  19816641]

[24]
Cheng Y, Bai L, Shang J, et al. Preliminary clinical results for PET/MR compared with PET/CT in patients with nasopharyngeal carcinoma. Oncol Rep  2020; 43(1): 177-87.
 [PMID:  31746412]

[25]
Liu Z, Chen Y, Su Y, Hu X, Peng X. Nasopharyngeal carcinoma: clinical achievements and considerations among treatment options. Front Oncol  2021; 11: 635737.
 [http://dx.doi.org/10.3389/fonc.2021.635737] [PMID:  34912697]

[26]
Liang Z, Zhu X, Li L, et al. Concurrent chemoradiotherapy followed by adjuvant chemotherapy compared with concurrent chemoradiotherapy alone for the treatment of locally advanced nasopharyngeal carcinoma: a retrospective controlled study. Curr Oncol  2014; 21(3): 408-17.
 [http://dx.doi.org/10.3747/co.21.1777] [PMID:  24940100]

[27]
Bossi P, Chan AT, Licitra L, et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol  2021; 32(4): 452-65.
 [http://dx.doi.org/10.1016/j.annonc.2020.12.007] [PMID:  33358989]

[28]
Zong J, Xu H, Chen B, et al. Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma. Radiat Oncol  2019; 14(1): 182.
 [http://dx.doi.org/10.1186/s13014-019-1387-9] [PMID:  31640719]

[29]
Pow EHN, Kwong DLW, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys  2006; 66(4): 981-91.
 [http://dx.doi.org/10.1016/j.ijrobp.2006.06.013] [PMID:  17145528]

[30]
Co J, Mejia MB, Dizon JM. Evidence on effectiveness of intensity-modulated radiotherapy versus 2-dimensional radiotherapy in the treatment of nasopharyngeal carcinoma: Meta-analysis and a systematic review of the literature. Head Neck  2016; 38(S1): E2130-42.
 [http://dx.doi.org/10.1002/hed.23977] [PMID:  25546181]

[31]
Peng G, Wang T, Yang K, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol  2012; 104(3): 286-93.
 [http://dx.doi.org/10.1016/j.radonc.2012.08.013] [PMID:  22995588]

[32]
Zhang B, Mo Z, Du W, Wang Y, Liu L, Wei Y. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. Oral Oncol  2015; 51(11): 1041-6.
 [http://dx.doi.org/10.1016/j.oraloncology.2015.08.005] [PMID:  26296274]

[33]
Ebner DK, Kamada T. The emerging role of carbon-ion radiotherapy. Front Oncol  2016; 6: 140.
 [http://dx.doi.org/10.3389/fonc.2016.00140] [PMID:  27376030]

[34]
Moreno AC, Frank SJ, Garden AS, et al. Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer. Oral Oncol  2019; 88: 66-74.
 [http://dx.doi.org/10.1016/j.oraloncology.2018.11.015] [PMID:  30616799]

[35]
Lewis GD, Holliday EB, Kocak-Uzel E, et al. Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. Head Neck  2016; 38(S1): E1886-95.
 [http://dx.doi.org/10.1002/hed.24341] [PMID:  26705956]

[36]
Morgan HE, Sher DJ. Adaptive radiotherapy for head and neck cancer. Cancers Head Neck  2020; 5(1): 1-16.
 [http://dx.doi.org/10.1186/s41199-019-0046-z] [PMID:  31938572]

[37]
Paiar F, Di Cataldo V, Zei G, et al. Role of chemotherapy in nasopharyngeal carcinoma. Oncol Rev  2012; 6(1): 1.
 [http://dx.doi.org/10.4081/oncol.2012.e1] [PMID:  25992199]

[38]
Colevas AD, Yom SS, Pfister DG, et al. NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Canc Netw  2018; 16(5): 479-90.
 [http://dx.doi.org/10.6004/jnccn.2018.0026] [PMID:  29752322]

[39]
Bhattacharyya T, Babu G, Kainickal CT. Current role of chemotherapy in nonmetastatic nasopharyngeal cancer. J Oncol  2018; 2018: 3725837.

[40]
Prabhash K, Gairola M, Babu G, et al. Indian clinical practice consensus guidelines for the management of nasopharyngeal cancer. Indian J Cancer  2020; 57(5) (Suppl.): 9.
 [http://dx.doi.org/10.4103/0019-509X.278974] [PMID:  32167065]

[41]
Chow JCH, Ngan RKC, Cheung KM, Cho WCS. Immunotherapeutic approaches in nasopharyngeal carcinoma. Expert Opin Biol Ther  2019; 19(11): 1165-72.
 [http://dx.doi.org/10.1080/14712598.2019.1650910] [PMID:  31361154]

[42]
Feng XP, Yi H, Li MY, et al. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res  2010; 70(9): 3450-62.
 [http://dx.doi.org/10.1158/0008-5472.CAN-09-4099] [PMID:  20406978]

[43]
Qu C, Liang Z, Huang J, et al. MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle  2012; 11(4): 785-96.
 [http://dx.doi.org/10.4161/cc.11.4.19228] [PMID:  22374676]

[44]
Li K, Zhu X, Li L, et al. Identification of non-invasive biomarkers for predicting the radiosensitivity of nasopharyngeal carcinoma from serum microRNAs. Sci Rep  2020; 10(1): 5161.
 [http://dx.doi.org/10.1038/s41598-020-61958-4] [PMID:  32198434]

[45]
Li LN, Xiao T, Yi HM, et al. MiR-125b increases nasopharyngeal carcinoma radioresistance by targeting A20/NF-kB signaling pathway. Mol Cancer Ther  2017; 16(10): 2094-106.
 [http://dx.doi.org/10.1158/1535-7163.MCT-17-0385] [PMID:  28698199]

[46]
Luftig M. Heavy LIFting: Tumor promotion and radioresistance in NPC. J Clin Invest  2013; 123(12): 4999-5001.
 [http://dx.doi.org/10.1172/JCI73416] [PMID:  24270417]

[47]
Czarny P, Pawlowska E, Bialkowska-Warzecha J, Kaarniranta K, Blasiak J. Autophagy in DNA damage response. Int J Mol Sci  2015; 16(2): 2641-62.
 [http://dx.doi.org/10.3390/ijms16022641] [PMID:  25625517]

[48]
Ameziane-El-Hassani R, Boufraqech M, Lagente-Chevallier O, et al. Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells. Cancer Res  2010; 70(10): 4123-32.
 [http://dx.doi.org/10.1158/0008-5472.CAN-09-4336] [PMID:  20424115]

[49]
Davalli P, Marverti G, Lauriola A, D’Arca D. Targeting oxidatively induced DNA damage response in cancer: opportunities for novel cancer therapies. Oxid Med Cell Longev  2018; 2018: 1-21.
 [http://dx.doi.org/10.1155/2018/2389523] [PMID:  29770165]

[50]
Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol  2007; 35(4): 495-516.
 [http://dx.doi.org/10.1080/01926230701320337] [PMID:  17562483]

[51]
Tang L, Wei F, Wu Y, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res  2018; 37(1): 87.
 [http://dx.doi.org/10.1186/s13046-018-0758-7] [PMID:  29688867]

[52]
Zhan Y, Fan S. Multiple mechanisms involving in radioresistance of nasopharyngeal carcinoma. J Cancer  2020; 11(14): 4193-204.
 [http://dx.doi.org/10.7150/jca.39354] [PMID:  32368302]

[53]
Allocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis  2018; 7(1): 8.
 [http://dx.doi.org/10.1038/s41389-017-0025-3] [PMID:  29362397]

[54]
Bocedi A, Noce A, Marrone G, et al. Glutathione transferase p1-1 an enzyme useful in biomedicine and as biomarker in clinical practice and in environmental pollution. Nutrients  2019; 11(8): 1741.
 [http://dx.doi.org/10.3390/nu11081741] [PMID:  31357662]

[55]
Harries L, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S- transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis  1997; 18(4): 641-4.
 [http://dx.doi.org/10.1093/carcin/18.4.641] [PMID:  9111193]

[56]
Chen X, Liang L, Hu X, Chen Y. Glutathione S-transferase P1 gene Ile105Val polymorphism might be associated with lung cancer risk in the Chinese Han population. Tumour Biol  2012; 33(6): 1973-81.
 [http://dx.doi.org/10.1007/s13277-012-0457-5] [PMID:  22797821]

[57]
AL-Eitan LN Rababa’h DM, Alghamdi MA, Khasawneh RH. Association of GSTM1, GSTT1 And GSTP1 polymorphisms with breast cancer among jordanian women. OncoTargets Ther  2019; 12: 7757-65.
 [http://dx.doi.org/10.2147/OTT.S207255] [PMID:  31571925]

[58]
Huang S, Wu F, Luo M, et al. The glutathione S-transferase P1 341C>T polymorphism and cancer risk: A meta-analysis of 28 case-control studies. PLoS One  2013; 8(2): e56722.
 [http://dx.doi.org/10.1371/journal.pone.0056722] [PMID:  23437223]

[59]
Ding F, Li JP, Zhang Y, Qi GH, Song ZC, Yu YH. Comprehensive analysis of the association between the rs1138272 polymorphism of the gstp1 gene and cancer susceptibility. Front Physiol  2019; 9: 1897.
 [http://dx.doi.org/10.3389/fphys.2018.01897] [PMID:  30740061]

[60]
Ge J, Tian AX, Wang QS, et al. The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China. PLoS One  2013; 8(6): e67589.
 [http://dx.doi.org/10.1371/journal.pone.0067589] [PMID:  23826324]

[61]
Tulsyan S, Chaturvedi P, Agarwal G, et al. Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: A multi-analytical approach. Mol Diagn Ther  2013; 17(6): 371-9.
 [http://dx.doi.org/10.1007/s40291-013-0045-4] [PMID:  23812950]

[62]
Deng X, Yang X, Cheng Y, et al. GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy. Sci Rep  2015; 5(1): 14000.
 [http://dx.doi.org/10.1038/srep14000]

[63]
Pincinato EC, Costa EFD, Lopes-Aguiar L, et al. GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation. Sci Rep  2019; 9(1): 9312.
 [http://dx.doi.org/10.1038/s41598-019-45808-6] [PMID:  31249357]

[64]
Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact  2006; 160(1): 1-40.
 [http://dx.doi.org/10.1016/j.cbi.2005.12.009] [PMID:  16430879]

[65]
Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J  2012; 5(1): 9-19.
 [http://dx.doi.org/10.1097/WOX.0b013e3182439613] [PMID:  23268465]

[66]
Lee CH, Lee KY, Choe KH, et al. [Effects of oxidative DNA damage and genetic polymorphism of the glutathione peroxidase 1 (GPX1) and 8-oxoguanine glycosylase 1 (hOGG1) on lung cancer].  J Prev Med Public Health  2006; 39(2): 130-4.
 [PMID:  16615267]

[67]
Paz-y-Miño C, Muñoz MJ, López-Cortés A, et al. Frequency of polymorphisms pro198leu in GPX-1 gene and ile58thr in MnSOD gene in the altitude Ecuadorian population with bladder cancer. Oncol Res  2009; 18(8): 395-400.
 [http://dx.doi.org/10.3727/096504010X12644422320780] [PMID:  20441054]

[68]
Kucukgergin C, Sanli O. Amasyalı AS, Tefik T, Seckin S. Genetic variants of MnSOD and GPX1 and susceptibility to bladder cancer in a Turkish population. Med Oncol  2012; 29(3): 1928-34.
 [http://dx.doi.org/10.1007/s12032-011-0057-z] [PMID:  21904836]

[69]
Trifa AP, Bănescu  C, Dima D, et al. Among a panel of polymorphisms in genes related to oxidative stress, CAT -262 C>T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms. Hematology  2016; 21(9): 520-5.
 [http://dx.doi.org/10.1080/10245332.2016.1163889] [PMID:  27077777]

[70]
Coskun C, Verim A, Farooqi AA, et al. Are there possible associations between MnSOD and GPx1 gene variants for laryngeal cancer risk or disease progression? Cell Mol Biol  2016; 62(5): 25-30.
 [PMID:  27188866]

[71]
Hadami K, Ameziane El Hassani R, Ameur A, et al. Association between GPX1 Pro189Leu polymorphism and the occurrence of bladder cancer in Morocco. Cell Mol Biol  2016; 62(14): 38-43.
 [http://dx.doi.org/10.14715/cmb/2016.62.14.6] [PMID:  28145855]

[72]
Nikic P, Dragicevic D, Savic-Radojevic A, et al. Association between GPX1 and SOD2 genetic polymorphisms and overall survival in patients with metastatic urothelial bladder cancer: A single-center study in Serbia. J BUON  2018; 23(4): 1130-5.
 [PMID:  30358222]

[73]
Yan J, Wang X, Tao H, Deng Z, Yang W, Lin F. Meta-Analysis of the Relationship between XRCC1-Arg399Gln and Arg280His Polymorphisms and the Risk of Prostate Cancer. Sci Rep  2015; 5(1): 1-9.

[74]
Singh SA, Ghosh SK. Polymorphisms of XRCC1 and XRCC2 DNA repair genes and interaction with environmental factors influence the risk of nasopharyngeal carcinoma in northeast India. Asian Pac J Cancer Prev  2016; 17(6): 2811-9.
 [PMID:  27356695]

[75]
Chen H, Wu M, Li G, Hua L, Chen S, Huang H. Association between XRCC1 single-nucleotide polymorphism and acute radiation reaction in patients with nasopharyngeal carcinoma. Medicine   2017; 96(44): e8202.
 [http://dx.doi.org/10.1097/MD.0000000000008202] [PMID:  29095251]

[76]
Lin J, Ye Q, Wang Y, Wang Y, Zeng Y. Association between XRCC1 single-nucleotide polymorphisms and susceptibility to nasopharyngeal carcinoma. Medicine   2018; 97(32): e11852.
 [http://dx.doi.org/10.1097/MD.0000000000011852] [PMID:  30095663]

[77]
Jin ZY, Zhao XT, Zhang LN, Wang Y, Yue WT, Xu SF. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. Genet Mol Res  2014; 13(3): 7617-25.
 [http://dx.doi.org/10.4238/2014.March.31.13] [PMID:  24737519]

[78]
Jin H, Xie X, Wang H, et al. ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma. PLoS One  2014; 9(7): e101256.
 [http://dx.doi.org/10.1371/journal.pone.0101256] [PMID:  25025378]

[79]
Zhai XM, Hu QC, Gu K, Wang JP, Zhang JN, Wu YW. Significance of XRCC1 Codon399 polymorphisms in Chinese patients with locally advanced nasopharyngeal carcinoma treated with radiation therapy. Asia Pac J Clin Oncol  2016; 12(1): e125-32.
 [http://dx.doi.org/10.1111/ajco.12117] [PMID:  23910235]

[80]
Du L, Yu W, Huang X, et al. GSTP1 Ile105Val polymorphism might be associated with the risk of radiation pneumonitis among lung cancer patients in Chinese population: A prospective study. J Cancer  2018; 9(4): 726-35.
 [http://dx.doi.org/10.7150/jca.20643] [PMID:  29556330]

[81]
Tian X, Tian Y, Ma P, et al. Association between the XRCC3 C241T polymorphism and lung cancer risk in the Asian population. Tumour Biol  2013; 34(5): 2589-97.
 [http://dx.doi.org/10.1007/s13277-013-0806-z] [PMID:  23749486]

[82]
Han S, Zhang HT, Wang Z, et al. DNA repair gene XRCC3 polymorphisms and cancer risk: A meta-analysis of 48 case-control studies. Eur J Hum Genet  2006; 14(10): 1136-44.
 [http://dx.doi.org/10.1038/sj.ejhg.5201681] [PMID:  16791138]

[83]
Mao CF, Qian WY, Wu JZ, Sun DW, Tang JH. Association between the XRCC3 Thr241Met polymorphism and breast cancer risk: an updated meta-analysis of 36 case-control studies. Asian Pac J Cancer Prev  2014; 15(16): 6613-8.
 [http://dx.doi.org/10.7314/APJCP.2014.15.16.6613] [PMID:  25169497]

[84]
Fan J, Liu W, Zhang M, Xing C. A literature review and systematic meta-analysis on XRCC3 Thr241Met polymorphism associating with susceptibility of oral cancer. Oncol Lett  2019; 18(3): 3265-73.
 [http://dx.doi.org/10.3892/ol.2019.10609] [PMID:  31452804]

[85]
Dong Z, Wang Y, Wang G. Association of X-ray cross-complementing group 3 Thr241Met gene polymorphism with osteosarcoma risk and its development and prognosis. J Cancer Res Ther  2018; 14(7) (Suppl.): 1178.
 [http://dx.doi.org/10.4103/0973-1482.199435] [PMID:  30539867]

[86]
Pei JS, Chang WS, Hsu PC, et al. The contribution of XRCC3 genotypes to childhood acute lymphoblastic leukemia. Cancer Manag Res  2018; 10: 5677-84.
 [http://dx.doi.org/10.2147/CMAR.S178411] [PMID:  30532590]

[87]
Yan L, Li Q, Li X, Ji H, Zhang L. Association studies between XRCC1, XRCC2, XRCC3 polymorphisms and differentiated thyroid carcinoma. Cell Physiol Biochem  2016; 38(3): 1075-84.
 [http://dx.doi.org/10.1159/000443058] [PMID:  26938431]

[88]
Kayani MA, Khan S, Baig RM, Mahjabeen I. Association of RAD 51 135 G/C, 172 G/T and XRCC3 Thr241Met gene polymorphisms with increased risk of head and neck cancer. Asian Pac J Cancer Prev  2015; 15(23): 10457-62.
 [http://dx.doi.org/10.7314/APJCP.2014.15.23.10457] [PMID:  25556492]

[89]
Stur E, Agostini LP, Garcia FM, et al. Prognostic significance of head and neck squamous cell carcinoma repair gene polymorphism. Genet Mol Res  2015; 14(4): 12446-54.
 [http://dx.doi.org/10.4238/2015.October.16.11] [PMID:  26505394]

[90]
Farnebo L, Stjernström A, Fredrikson M, Ansell A, Garvin S, Thunell LK. DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck. DNA Repair  2015; 31: 64-72.
 [http://dx.doi.org/10.1016/j.dnarep.2015.05.003] [PMID:  26001739]

[91]
de Almeida VH, de Melo AC, Meira DD, et al. Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer. Braz J Med Biol Res  2018; 51(1): e6822.
 [http://dx.doi.org/10.1590/1414-431x20176822] [PMID:  29160417]

[92]
Mehra R, Zhu F, Yang DH, et al. Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res  2013; 19(23): 6633-43.
 [http://dx.doi.org/10.1158/1078-0432.CCR-13-0152] [PMID:  24088734]

[93]
Rao D, Mallick AB, Augustine T, et al. Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin. Oncotarget  2019; 10(53): 5510-22.
 [http://dx.doi.org/10.18632/oncotarget.27140] [PMID:  31565185]

[94]
Dai P, Li J, Li W, et al. Genetic polymorphisms and pancreatic cancer risk. Medicine (Baltimore)  2019; 98(32): e16541.
 [http://dx.doi.org/10.1097/MD.0000000000016541] [PMID:  31393355]

[95]
Cai L-M, Lyu X-M, Luo W-R, et al. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. Oncogene  2015; 34(17): 2156-66.
 [http://dx.doi.org/10.1038/onc.2014.341] [PMID:  25347742]

[96]
Fan C, Tang Y, Wang J, et al. The emerging role of Epstein-Barr virus encoded microRNAs in nasopharyngeal carcinoma. J Cancer  2018; 9(16): 2852-64.
 [http://dx.doi.org/10.7150/jca.25460] [PMID:  30123354]

[97]
Wang S, Pan Y, Zhang R, et al. Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3′UTR and 5′UTR of Jab1/CSN5. Oncogene  2016; 35(47): 6096-108.
 [http://dx.doi.org/10.1038/onc.2016.147] [PMID:  27157611]

[98]
Zhang Y, Zheng L, Huang J, et al. MiR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1. PLoS One  2014; 9(4): e93917.
 [http://dx.doi.org/10.1371/journal.pone.0093917] [PMID:  24705396]

[99]
Lung RWM, Hau PM, Yu KHO, et al. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma. J Pathol  2018; 244(4): 394-407.
 [http://dx.doi.org/10.1002/path.5018] [PMID:  29230817]

[100]
Wu Q, Han T, Sheng X, Zhang N, Wang P. Downregulation of EB virus miR-BART4 inhibits proliferation and aggressiveness while promoting radiosensitivity of nasopharyngeal carcinoma. Biomed Pharmacother  2018; 108: 741-51.
 [http://dx.doi.org/10.1016/j.biopha.2018.08.146] [PMID:  30248542]

[101]
Chen ZX, Sun AM, Chen Y, et al. (Effects of radiosensitivity and X-ray dose on miR-7 expression in nasopharyngeal carcinoma). Nan Fang Yi Ke Da Xue Xue Bao  2010; 30(8): 1810-1812,1816.
 [PMID: 20813671]

[102]
Tan G, Tang X, Tang F. The role of microRNAs in nasopharyngeal carcinoma. Tumour Biol  2015; 36(1): 69-79.
 [http://dx.doi.org/10.1007/s13277-014-2847-3] [PMID:  25427638]

[103]
Xu J, Ai Q, Cao H, Liu Q. MiR-185-3p and miR-324-3p predict radiosensitivity of nasopharyngeal carcinoma and modulate cancer cell growth and apoptosis by targeting SMAD7. Med Sci Monit  2015; 21: 2828-36.
 [http://dx.doi.org/10.12659/MSM.895660] [PMID:  26390174]

[104]
Tian Y, Yan M, Zheng J, et al. miR-483-5p decreases the radiosensitivity of nasopharyngeal carcinoma cells by targeting DAPK1. Lab Invest  2019; 99(5): 602-11.
 [http://dx.doi.org/10.1038/s41374-018-0169-6] [PMID:  30664712]

[105]
Duan B, Shi S, Yue H, et al. Exosomal miR-17-5p promotes angiogenesis in nasopharyngeal carcinoma via targeting BAMBI. J Cancer  2019; 10(26): 6681-92.
 [http://dx.doi.org/10.7150/jca.30757] [PMID:  31777597]

[106]
Ni J, Bucci J, Malouf D, Knox M, Graham P, Li Y. Exosomes in Cancer Radioresistance. Front Oncol  2019; 9: 869.
 [http://dx.doi.org/10.3389/fonc.2019.00869] [PMID:  31555599]

[107]
Guo Y, Zhu XD, Qu S, et al. Identification of genes involved in radioresistance of nasopharyngeal carcinoma by integrating gene ontology and protein-protein interaction networks. Int J Oncol  2012; 40(1): 85-92.
 [PMID:  21874234]

[108]
Zhang L, Su B, Sun W, et al. Twist1 promotes radioresistance in nasopharyngeal carcinoma. Oncotarget  2016; 7(49): 81332-40.
 [http://dx.doi.org/10.18632/oncotarget.12875] [PMID:  27793033]

[109]
Zhang MX, Wang L, Zeng L, Tu ZW. LCN2 is a potential biomarker for radioresistance and recurrence in nasopharyngeal carcinoma. Front Oncol  2021; 10: 605777.
 [http://dx.doi.org/10.3389/fonc.2020.605777] [PMID:  33604288]

[110]
Xiao J, He X. Involvement of non-coding RNAs in chemo- and radioresistance of nasopharyngeal carcinoma. Cancer Manag Res  2021; 13: 8781-94.
 [http://dx.doi.org/10.2147/CMAR.S336265] [PMID:  34849030]

[111]
Zhang G, Zhang K, Li C, et al. Serum proteomics identify potential biomarkers for nasopharyngeal carcinoma sensitivity to radiotherapy. Biosci Rep  2019; 39(5): BSR20190027.
 [http://dx.doi.org/10.1042/BSR20190027] [PMID:  31040200]
Cite As
Current Pharmacogenomics and Personalized Medicine

Recent Advances in Nasopharyngeal Cancer Management: From Diagnosis to Theranostics

Abstract
